Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K31/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/182077USE OF GLI2 INHIBITOR AND METHOD FOR SCREENING COMPOUND INHIBITING GLI2
WO 17.09.2020
Int.Class C07C 405/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
405Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins
Appl.No PCT/CN2020/078224 Applicant INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES Inventor WANG, Yu
A prostaglandin as represented by formula I and an analog thereof used as medicines, and a pharmaceutical composition containing the compounds, particularly used as an inhibitor of zinc finger domain-containing protein GLI2 (i.e., glioma-associated oncogene-2), and used for treatment, prevention, or alleviation of tumors (particularly tumor resistance) in subjects, or neurodegenerative diseases or developmental syndromes and malformations caused by dysregulation of signaling pathways involving GLI2. Also provided is a method for screening a compound inhibiting GLI2.
2.WO/2020/182927POTASSIUM-BINDING AGENTS FOR USE IN HEMODIALYSIS PATIENTS
WO 17.09.2020
Int.Class A61K 33/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
Appl.No PCT/EP2020/056595 Applicant ASTRAZENECA AB Inventor JONASSON, Jenny
The present invention relates to the use of potassium-binding agents that are formulated to remove toxins, e.g., potassium ions, from the gastrointestinal tract at an elevated rate, without causing undesirable side effects, in hemodialysis patients. The compositions exhibit desired characteristics for the long term administration to treat or prevent the relapse or occurrence of certain conditions, for example hyperkalemia.
3.WO/2020/182947MACROCYCLES WITH ANTIOXIDANT AND NEUROPROTECTIVE ACTIVITIES
WO 17.09.2020
Int.Class A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Appl.No PCT/EP2020/056665 Applicant INSTITUTO BIOMAR, S.A Inventor FERNÁNDEZ MEDARDE, Antonio
Compounds of general formula wherein the wavy bond ~ is either a double bond or the epoxide, or pharmaceutically acceptable salts, solvates, tautomers, or stereoisomers thereof, for use in the treatment of diseases associated with oxidative stress.
4.WO/2020/183227TREATING INFLUENZA USING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES AND PRODRUGS THEREOF IN A SUBJECT HAVING INFLUENZA AND A COMPLICATION RISK FACTOR
WO 17.09.2020
Int.Class A61K 31/5383
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5383ortho- or peri-condensed with heterocyclic ring systems
Appl.No PCT/IB2019/052012 Applicant SHIONOGI & CO., LTD. Inventor UEHARA, Takeki
A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound, for example baloxavir marboxil, to a subject having an influenza virus infection and at least one complication risk factor. Generally, the amount is effective such that a reduction in a time to improvement of at least one symptom of an influenza virus infection is statistically significant as compared to that of a non-treated subject.
5.WO/2020/183307DIHYDRO-SPIRO[INDOLINE-3:1'-ISOQUINOLIN]-2-ONES AND THEIR ANALOGUES AND DERIVATIVES AND METHODS OF TREATING CANCER AND OTHER DISEASES
WO 17.09.2020
Int.Class C07D 471/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
10Spiro-condensed systems
Appl.No PCT/IB2020/051930 Applicant THE UNIVERSITY OF BUEA Inventor MABANYI, Lobe Maloba Mesembe
The present invention is directed to various 3',4'-dihydro-2'H-spiro[indoline-3:1'-isoquinolin]-2-one compounds and methods for treating disease states and/or conditions which are mediated through sphingosine-1-phosphate receptor(s). The present invention is also directed to the use of these compounds as anticancer agents and as modulators of sphingosine-1-phosphate receptor function in the treatment of disease states and/or conditions which are mediated through these receptors. In addition, the invention relates to pharmaceutical compositions comprising one or more of these compounds alone or in combination with other therapeutic agents. The invention is also directed to methods of treatment of cancer and/or conditions that may respond to the modulation of sphingosine-1-phospate receptor function and which employ compounds of the present invention or pharmaceutical compositions comprising one or more of the compounds of this invention.
6.WO/2020/183457CANNABINOID COMBINATIONS FOR TREATING DIABETIC NEUROPATHY
WO 17.09.2020
Int.Class A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Appl.No PCT/IL2020/050272 Applicant BOL PHARMA LTD. Inventor GEDO, Tamir
The present invention is directed to a cannabinoid combination comprising, as the only cannabinoids, cannabidiol (CBD) and A9-tetrahydrocannabinol (THC), or enantiomers, diastereomers, or racemates thereof, for use in the treatment of diabetic neuropathy in a subject, or for improving the efficacy and/or reducing adverse effects of a standard of care (SoC) drug for treating neuropathic pain, wherein the CBD:THC weight ratio in the cannabinoid combination is about of 4:1 to about 10:1.
7.WO/2020/184677ANTI-HEPATITIS B VIRUS AGENT
WO 17.09.2020
Int.Class A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Appl.No PCT/JP2020/010910 Applicant DAIKIN INDUSTRIES, LTD. Inventor HAMADA, Tomohito
The present invention addresses the problem of providing an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-associated diseases, containing a nucleic acid analog as an active ingredient. The problem can be solved by an anti-hepatitis B virus agent and a prophylactic or therapeutic agent for hepatitis B virus-associated diseases, containing, as an active ingredient, a compound represented by formula (1) (in the formula, R represents a halogen atom, an amino group, a methoxy group, or a cyano group) or a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a solvate thereof.
8.WO/2020/185677BIO-RESPONSIVE ANTIBODY COMPLEXES FOR ENHANCED IMMUNOTHERAPY
WO 17.09.2020
Int.Class A61K 31/7068
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7042Compounds having saccharide radicals and heterocyclic rings
7052having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
706containing six-membered rings with nitrogen as a ring hetero atom
7064containing condensed or non-condensed pyrimidines
7068having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Appl.No PCT/US2020/021709 Applicant NORTH CAROLINA STATE UNIVERSITY Inventor GU, Zhen
Disclosed are bioresponsive protein complexes comprising immune checkpoint blockade inhibitors and methods of their use.
9.WO/2020/186027INHIBITORS OF CGAS FOR TREATING AUTOINFLAMMATORY DISEASES AND CANCER METASTASIS
WO 17.09.2020
Int.Class A61K 31/437
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
437the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Appl.No PCT/US2020/022334 Applicant TOMITA, Daisuke Inventor TOMITA, Daisuke
Tri-cyclyl nitrogen-containing heterocyclic compounds are disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.
10.WO/2020/186187METHODS FOR TREATING BLADDER AND URETHRA DYSFUNCTION AND DISEASE
WO 17.09.2020
Int.Class A61K 31/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
52Purines, e.g. adenine
522having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
Appl.No PCT/US2020/022697 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor JACKSON, Edwin Kerry
Methods of treating bladder or urethra dysfunction or disease in a subject and methods of increasing bladder smooth muscle contractility or increasing bladder wall volume in a subject are disclosed. In some examples, a purine nucleoside phosphorylase (PNPase) inhibitor or purine nucleoside substrate is administered, such as 8-aminoguanine or forodesine.